Kronos Bio
San Mateo
About Kronos Bio
Kronos Bio focuses on the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets. It develops therapies that modulate historically undruggable targets. The company leverages deep capabilities in high-throughput small-molecule microarrays (SMM), targeted protein degradation, and cancer biology in order to identify potent and selective compounds against transcription factors and other central drivers of oncogenic signaling.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $278.0M
- Funding stage: M&A
- Last round: Private Equity (Aug 2020)
- Ticker: nasdaq:KRON
- Website: kronosbio.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Chemical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/kronos-bio-47061 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.